c-Met inhibitor 1 - CAS 1357072-61-7
Catalog number: 1357072-61-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C17H14N8S
Molecular Weight:
362.41
COA:
Inquire
Targets:
c-Met/HGFR
Description:
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
c-Met inhibitor 1
MSDS:
Inquire
1.Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
Liu TC1,2, Peng X3, Ma YC2, Ji YC3, Chen DQ2, Zheng MY2, Zhao DM1, Cheng MS1, Geng MY3, Shen JK2, Ai J3, Xiong B2. Acta Pharmacol Sin. 2016 Apr 4. doi: 10.1038/aps.2016.11. [Epub ahead of print]
AIM: Aberrant c-Met activation plays a critical role in cancer formation, progression and dissemination, as well as in development of resistance to anticancer drugs. Therefore, c-Met has emerged as an attractive target for cancer therapy. The aim of this study was to develop new c-Met inhibitors and elaborate the structure-activity relationships of identified inhibitors.
2.MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Awad MM1, Oxnard GR2, Jackman DM2, Savukoski DO2, Hall D2, Shivdasani P2, Heng JC2, Dahlberg SE2, Jänne PA2, Verma S2, Christensen J2, Hammerman PS2, Sholl LM2. J Clin Oncol. 2016 Mar 1;34(7):721-30. doi: 10.1200/JCO.2015.63.4600. Epub 2016 Jan 4.
PURPOSE: Non-small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical, pathologic, and genomic characteristics of patients with cancer with MET exon 14 mutations.
3.Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X1, Bao G2, Wang L2, Cheng M3, Zhao M2, Zhao S2, Zhou H2, Gong P4. Bioorg Med Chem. 2016 Mar 15;24(6):1331-45. doi: 10.1016/j.bmc.2016.02.003. Epub 2016 Feb 4.
In continuing our efforts to identify small molecules able to inhibit c-Met kinase, three series of novel 6,7-disubstituted-4-phenoxyquinoline derivatives (23a-w, 26a-d and 30a-d) bearing (thio)semicarbazone scaffold were designed, synthesized and evaluated for their cytotoxicity. The biological data revealed that most compounds exhibited moderate-to-excellent activity against HT-29, MKN-45, A549 cancer cell lines and relative poor potency toward MDA-MB-231 cell as well as hardly any cytotoxicity in normal PBL cell. Eleven compounds were further examined for their inhibitory activity against c-Met kinase and three compounds (23h, 23n and 26a) demonstrated good inhibitory activity. This work resulted in the discovery of a potent c-Met inhibitor 23n, bearing 2-hydroxy-3-allylphenyl group at R(2) moiety, as a valuable lead molecule, which possessed remarkable cytotoxicity and high selectivity against A549 and HT-29 cell lines with IC50 values of 11nM and 27nM.
4.Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.
Zhan Z1, Peng X2, Liu Q3, Chen F1, Ji Y2, Yao S1, Xi Y2, Lin Y1, Chen T3, Xu Y4, Ai J5, Geng M6, Duan W7. Eur J Med Chem. 2016 Mar 31;116:239-251. doi: 10.1016/j.ejmech.2016.03.076. [Epub ahead of print]
c-Met/HGF overexpression has been detected in many human malignancies including tumors which are resistant to anticancer therapy. Disrupting the aberrant c-Met/HGF axis has enjoyed significant progress in both preclinical and clinical antitumor campaign. To eliminate the OCH2-related metabolic deficiency of our previously reported triazolotriazine 2, we synthesized a series of CH2-/CF2-linked triazolotriazines and assessed their c-Met activities, leading to the highly potent compound 23 with IC50 values of 0.24 nM of enzymatic activity in c-Met and 0.85 nM of cellular activity in EBC-1 cancer cell line, as well as with complete tumor regression in EBC-1 xenograft mice model at dose of 25 mg/kg via oral administration. Based on its potent anti-proliferative activities and favorable pharmacokinetic properties, 23 has been selected as a drug candidate for preclinical investigation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related c-Met/HGFR Products


CAS 905854-02-6 Tivantinib

Tivantinib
(CAS: 905854-02-6)

Tivantinib (ARQ-197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-...

CAS 1206801-37-7 LY2801653 dihydrochloride

LY2801653 dihydrochloride
(CAS: 1206801-37-7)

LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (K(i)) of 2 nM, a pharmacodynamic residence time ...

Glesatinib hydrochloride
(CAS: 1123838-51-6)

The hydrochloride salt form of Glesatinib, an inhibitor of tyrosine kinase, could be effectively targeting tumors that are driving to grow through MET and AXL r...

CAS 1001917-37-8 MK-8033

MK-8033
(CAS: 1001917-37-8)

MK8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.

CAS 1021950-26-4 Tyrosine kinase inhibitor

Tyrosine kinase inhibitor
(CAS: 1021950-26-4)

It is a Tyrosine kinase inhibitor.

CAS 1357072-61-7 c-Met inhibitor 1

c-Met inhibitor 1
(CAS: 1357072-61-7)

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic can...

CAS 1391426-24-6 Lys01 trihydrochloride

Lys01 trihydrochloride
(CAS: 1391426-24-6)

Lys01 trihydrochloride, a water-soluble salt of Lys01, is a selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respec...

CAS 1100598-32-0 Tepotinib

Tepotinib
(CAS: 1100598-32-0)

Tepotinib, also known as EMD 1214063 and MSC2156119, is an inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibito...

CAS 1002304-34-8 AMG208

AMG208
(CAS: 1002304-34-8)

AMG 208 is a selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. C-Met encodes the hepatocyte growth factor r...

CAS 956905-27-4 PF-04217903

PF-04217903
(CAS: 956905-27-4)

PF-04136309 is an orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral adminis...

CAS 477575-56-7 PHA665752

PHA665752
(CAS: 477575-56-7)

PHA665752 is a small-molecule inhibitor of c-Met/HGF/SF signaling c-Met is highly expressed in most tumors from patients with advanced-stage, metastatic NBL....

CAS 943540-75-8 JNJ-38877605

JNJ-38877605
(CAS: 943540-75-8)

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.

CAS 877399-52-5 Crizotinib

Crizotinib
(CAS: 877399-52-5)

Crizotinib is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.

CAS 1022150-57-7 SGX-523

SGX-523
(CAS: 1022150-57-7)

SGX523 is a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited MET with an IC50 of 4 nmol/L an...

AMG-337
(CAS: 1173699-31-4)

AMG 337 is an orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 337 selectively binds to c-M...

CAS 1029712-80-8 Capmatinib

Capmatinib
(CAS: 1029712-80-8)

Capmatinib, also known as INCB28060 and INC280,  is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with...

CAS 1313725-88-0 Savolitinib

Savolitinib
(CAS: 1313725-88-0)

Savolitinib is a tyrosine kinase inhibitor with potential anticancer activity.

CAS 1206799-15-6 LY2801653

LY2801653
(CAS: 1206799-15-6)

LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity.

SCR-1481B1
(CAS: 1174161-86-4)

SCR-1481B1, also known as c-Met inhibitor 2, is an effective inhibitor of MET kinase so that probably has anti-tumor activity. It is also found to be an inhibit...

LCRF-0004
(CAS: 1229611-73-7)

This active molecular is a selective RON receptor tyrosine kinase inhibitor. The RON receptor tyrosine kinase has been reported that it usually overexpressed in...

Chemical Structure

CAS 1357072-61-7 c-Met inhibitor 1

Quick Inquiry

Verification code

Featured Items